Shares of Titan Pharmaceuticals Inc. (NASDAQ:TTNP) climbed 34.2 percent to close at $1.65 on Friday after the drugmaker heralded a double-digit increase in shipments of its implantable opioid addiction maintenance product, Probuphine (buprenorphine). Titan, which regained U.S. and Canadian commercial rights to Probuphine from Braeburn Inc. in May 2018, attributed the improvement in part to its recruitment of new commercial and medical affairs personnel, its re-engagement with prescribers and efforts to better identify areas where it can be most successful. Read More
HONG KONG – Chinese drug regulators have granted the first marketing clearance to a homegrown dipeptidyl peptidase-4 (DPP-4) inhibitor for treating type 2 diabetes, developed by Jiangsu Aosaikang Pharmaceutical Co. Ltd. The saxagliptin tablet, which comes in 5 mg or 2.5 mg, is registered as a category IV chemical drug – a generic with equivalent quality and efficacy to the originator's drugs that are already marketed in China. Read More
The biopharmaceutical sector has quickly rebounded after its dismal December performance, where it shed almost 8 percent in valuation, and it hasn't taken long for biotech investors to shake off their bear mindset. In fact, they have been generally more upbeat following the 37th Annual J.P. Morgan Healthcare Conference. As a result, the BioWorld Biopharmaceutical index outpaced the general markets and recouped its loss and then some and returned a significant 10 percent gain in value in January, compared with the Dow Jones Industrial Average, which gained 7 percent. (See BioWorld Biopharmaceutical index, below.) Read More
Epizyme Inc. recently charmed investors by disclosing its brisker path forward with EZH2 inhibitor tazemetostat in follicular lymphoma (FL), and drew more attention to the subtype of non-Hodgkin lymphoma (NHL). Read More
After months of talking about doing away with the current rebate system, Health and Human Services (HHS) Secretary Alex Azar proposed a rule late Thursday that removes the safe harbor for drug manufacturer rebates paid to pharmacy benefit managers (PBMs). Read More
Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said it received notice from the NYSE American LLC that the company was granted an extension to March 31 to regain compliance with listing standards. Read More
Cancer Genetics Inc., of Rutherford, N.J., said it closed its public offering of about 15.2 million shares priced at 23 cents each. Gross proceeds totaled about $3.5 million. H.C. Wainwright & Co. acted as the sole placement agent. Read More
